Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
Weekly Insulin: Convenience or Concern? What the Latest Trials Reveal
This episode of Rethinking Diabetes breaks down the newest evidence on once-weekly basal insulin, including data from five major trials and the surprising safety concerns that emerged. We explore real-world implications, from hypoglycemia risk to CGM-guided titration, and what it all means for patient selection, adherence, and the future of diabetes care.
Bibliography
- Abunada S, et al. Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once-Weekly Basal Insulin Fc vs Insulin Degludec: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2025;8(4):e70067. doi:10.1002/edm2.70067.
- Riddell MC, et al. Effect of Once-Weekly Insulin Icodec vs Daily Basal Insulin on Exercise-Related Hypoglycaemia: Post Hoc Analysis of ONWARDS 1–5. Diabetologia. 2025;68(7):1416–1422. doi:10.1007/s00125-025-06414-6.
- Bergenstal RM, et al. CGM-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Type 2 Diabetes (ONWARDS 9). Diabetes Technol Ther. 2025;27(7):527–536. doi:10.1089/dia.2025.0050.
